The Use of Reduction of Splenomegaly as a Parameter for Therapeutic Response in Hepatic Schistosomiasis
DOI:
https://doi.org/10.5915/23-2-15068Keywords:
Schistosomiasis, splenomegaly, praziquante/Abstract
DOI: http://dx.doi.org/10.5915/23-2-15068
The effectiveness of praziquantel in the treatment of hepatic schistosomiasis was studied in 30 patients with bilharzial splenomegaly. Reduction in splenomegaly was used as a parameter of therapeutic success. Twenty one out of 30 patients improved when treated by repeated doses of praziquantel. The number of administered doses necessary to achieve clinical improvement was directly related to the pretreatment size of the spleen. The patients were divided into three groups according to the size of the spleen; up to 5 cm below the costal margin in the mid-clavicular line (Group 1), between 5-10 cm in Group 2, and more than 10 cm in Group 3. The rate of improvement was 100% in Group I, 75% in Group 2, and 25% in Group 3.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
